机构:[a]Department of Pharmacology, Xuanwu Hospital of Capital Medical University,Beijing Institute for Brain disorder,Beijing Engineering Research Center for Nerve System Drugs,Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing, China神经变性病教育部重点实验室首都医科大学宣武医院[b]First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China[c]Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China
Background: An accumulation of hyperphosphorylated tau in the brain is a hallmark of Alzheimer's disease (AD). Deficits in protein phosphatase 2A (PP2A) are associated with tau hyperphosphorylation in AD. Objective: To investigate the effects of morroniside (MOR), isolated from Cornus officinalis, on tau hyperphosphorylation and its underlying mechanisms related to PP2A. Methods: SK-N-SH cells were pretreated with 50-200 mu M MOR for 24 h followed by 20 nM okadaic acid (OA) for 6 h. PP2Ac siRNA was transfected into HEK293 cells to determine the direct interaction of MOR with PP2A. Western blotting was used to measure the expression of proteins and enzymes. PP2A activity was measured by molybdenum blue spectrophotometry. Results: Pretreatment with MOR improved the cellular morphological damage and inhibited tau hyperphosphorylation in SK-N-SH cells induced by OA, a PP2A inhibitor. Moreover, MOR increased PP2A activity, concurrent with a decrease in the expression of demethylated PP2A at Leu309 and phosphorylated PP2A at Tyr307. MOR decreased protein phosphatase methylesterase 1 (PME-1) expression and the ratio of PME-1/leucine carboxyl methyltransferase 1 (LCMT-1). Furthermore, MOR treatment decreased the phosphorylation of Src at Tyr416, which regulates the phosphorylation of PP2A. MOR had no effect on PP2Ac expression and tau hyperphosphorylation in PP2Ac siRNA-transfected cells. Conclusion: MOR attenuated OA-induced tau hyperphosphorylation via PP2A activation, and its mechanism might be related to the regulation of PP2Ac post-translational modification and upstream enzymes such as Src and PME-1.
基金:
National Natural Science Foundation of China (Nos. 81473373,81274120),
Beijing Natural Science Foundation(No. 7132110),
Beijing Health and Technical Personal of High-level Plan (Nos. 2014-2-014, 2011-1-7),
National Science and Technology Major Project for Essential Drug Research and Development (No. 2015ZX09101016).
第一作者机构:[a]Department of Pharmacology, Xuanwu Hospital of Capital Medical University,Beijing Institute for Brain disorder,Beijing Engineering Research Center for Nerve System Drugs,Key Laboratory for Neurodegenerative Diseases of Ministry of Education, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[*1]Department of Pharmacology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.
推荐引用方式(GB/T 7714):
Cui-cui Yang,Xue-xian Kuai,Wen-bin Gaoa ,et al.Morroniside-Induced PP2A Activation Antagonizes Tau Hyperphosphorylation in a Cellular Model of Neurodegeneration[J].JOURNAL OF ALZHEIMERS DISEASE.2016,51(1):33-44.doi:10.3233/JAD-150728.
APA:
Cui-cui Yang,Xue-xian Kuai,Wen-bin Gaoa,,Jian-chun Yu,Qi Wang...&Lan Zhang.(2016).Morroniside-Induced PP2A Activation Antagonizes Tau Hyperphosphorylation in a Cellular Model of Neurodegeneration.JOURNAL OF ALZHEIMERS DISEASE,51,(1)
MLA:
Cui-cui Yang,et al."Morroniside-Induced PP2A Activation Antagonizes Tau Hyperphosphorylation in a Cellular Model of Neurodegeneration".JOURNAL OF ALZHEIMERS DISEASE 51..1(2016):33-44